KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Krystal Biotech, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$320.25+3.67 (+1.16%)
Close on Oct 19, 2026
- Market cap
- $9.82B
- P/E (TTM)
- 40.1
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Operating margin
41.5%
Net margin
52.6%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +33.9% | – | – | – | |
| Operating income | +145.3% | – | – | – | |
| Net income | +129.7% | – | – | – | |
| EPS, diluted | +128.0% | – | – | – | |
| Free cash flow | +58.5% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -13.0% | 18.9% | |
| Return on assets | – | -12.4% | 17.1% | |
| Current ratio | 50.44 | 17.80 | 9.95 | |
| Capex to revenue | – | – | 3.1% | |
| Diluted shares | 1M | 19M | 30M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Krystal Biotech generated $561.60M from operations and spent $149.30M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$561.60M
Used
$149.30M
Capital expenditure$149.30M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin52.6%
×Asset turnover0.33×
×Equity multiplier1.10×
=Return on equity, FY202518.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 52.6% | 0.33× | 1.10× | 18.9% |
| FY2024 | 30.7% | 0.31× | 1.09× | 10.3% |
| FY2023 | 21.6% | 0.07× | 1.06× | 1.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$204.83M
- Cash generatingOperating cash flow above zero$200.87M
- Return on assets improvedROA up on the prior year10.9% → 19.4%
- Earnings backed by cashOperating cash flow above net income$200.87M vs $204.83M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.28 → 9.95
- No dilutionShare count did not rise30M → 30M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.35 → 0.37